Welcome. Already a member? Click here to sign in.
New customer? Click here  to begin.
Free Shipping on orders over $39.00
Vet Approved PET Medications - for LESS...   @VetApprovedRx.com
Call Toll Free: 877.847.7389
Show me products used for:   Dogs   Cats    > All <


Rimadyl caplets contain carprofen, an NSAID of the propionic acid class. It is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.

For oral use in dogs only.

Add this item to your cart:

Item# Size/Desc Qty Price
25 mg caplets 30 count
This item requires a RX
25 mg caplets 60 count
Item qualifies for FREE SHIPPINGThis item requires a RX
25 mg caplets 180 count
Item qualifies for FREE SHIPPINGThis item requires a RX
75 mg caplets 30 count
This item requires a RX
75 mg caplets 60 count
Item qualifies for FREE SHIPPINGThis item requires a RX
75 mg caplets 180 count
Item qualifies for FREE SHIPPINGThis item requires a RX
100 mg caplets 30 count
Item qualifies for FREE SHIPPINGThis item requires a RX
100 mg caplets 60 count
Item qualifies for FREE SHIPPINGThis item requires a RX
100 mg caplets 180 count
Item qualifies for FREE SHIPPINGThis item requires a RX

**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she will need to sign and return before we can ship you this product.

What is Rimadyl?:

Rimadyl carprofen is a non-steroidal anti-inflammatory drug NSAID developed and approved specifically for use in dogs. Indicated for the relief of pain and inflammation, Rimadyl has been shown to be clinically effective for the relief of signs associated with arthritis.


  • Canine non-steroidal anti-inflammatory drug NSAID in oral dosage form
  • Selectively inhibits cyclooxygenase COX-2, which generates prostaglandins involved in inflammation. In vitro, clinical relevance has not been shown.
  • Once-daily dosage provides anti-inflammatory and analgesic effects for 24 hours.



    Always follow the prescription instructions given to you by your prescribing veterinrian.
    Carefully consider the potential benefits and risk of Rimadyl and other treatment options before deciding to use Rimadyl.
    Use the lowest effective dose for the shortest duration consistent with individual response.
    The recommended dosage for oral administration to dogs is 2 mg/lb 4.4 mg/kg of body weight daily.
    The total daily dose may be administered as 2 mg/lb of body weight once daily or divided and administered as 1 mg/lb 2.2 mg/kg twice daily. For the control of postoperative pain, administer approximately 2 hours before the procedure.
    Caplets are scored and dosage should be calculated in half-caplet increments.


    Rimadyl is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.


    Rimadyl should not be used in dogs exhibiting previous hypersensitivity to carprofen.


    Keep out of reach of children. Not for human use.
    Consult a physician in cases of accidental ingestion by humans.
    For use in dogs only. Do not use in cats.

    All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID should be considered. Owners should be advised to observe for signs of potential drug toxicity see Information for Dog Owners, Adverse Reactions, Animal Safety and Post-Approval Experience.


    As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Effects may result from decreased prostaglandin production and inhibition of the enzyme cyclooxygenase which is responsible for the formation of prostaglandins from arachidonic acid.11-14 When NSAIDs inhibit prostaglandins that cause inflammation they may also inhibit those prostaglandins which maintain normal homeostatic function. These anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease more often than in healthy patients.12,14 NSAID therapy could unmask occult disease which has previously been undiagnosed due to the absence of apparent clinical signs. Patients with underlying renal disease for example, may experience exacerbation or decompensation of their renal disease while on NSAID therapy.11-14 The use of parenteral fluids during surgery should be considered to reduce the potential risk of renal complications when using NSAIDs perioperatively.

    Carprofen is an NSAID, and as with others in that class, adverse reactions may occur with its use. The most frequently reported effects have been gastrointestinal signs. Events involving suspected renal, hematologic, neurologic, dermatologic, and hepatic effects have also been reported. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be approached cautiously, with appropriate monitoring. Concomitant use of Rimadyl with other anti-inflammatory drugs, such as other NSAIDs or corticosteroids, should be avoided because of the potential increase of adverse reactions, including gastrointestinal ulcerations and/or perforations. Sensitivity to drug-associated adverse reactions varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Rimadyl treatment was not associated with renal toxicity or gastrointestinal ulceration in well-controlled safety studies of up to ten times the dose in healthy dogs.

    Rimadyl is not recommended for use in dogs with bleeding disorders e.g., Von Willebrand&rsquos disease, as safety has not been established in dogs with these disorders. The safe use of Rimadyl in animals less than 6 weeks of age, pregnant dogs, dogs used for breeding purposes, or in lactating bitches has not been established. Studies to determine the activity of Rimadyl when administered concomitantly with other protein-bound or similarly metabolized drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring additional therapy. Such drugs commonly used include cardiac, anticonvulsant and behavioral medications. It has been suggested that treatment with carprofen may reduce the level of inhalant anesthetics needed.15

    If additional pain medication is warranted after administration of the total daily dose of Rimadyl, alternative analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.


    Rimadyl, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include decreased appetite, vomiting, diarrhea, dark or tarry stools, increased water consumption, increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes. Serious adverse reactions associated with this drug class can occur without warning and in rare situations result in death see Adverse Reactions. Owners should be advised to discontinue Rimadyl therapy and contact their veterinarian immediately if signs of intolerance are observed. The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate, is initiated. Owners should be advised of the importance of periodic follow up for all dogs during administration of any NSAID.


    During investigational studies of osteoarthritis with twice daily administration of 1 mg/lb, no clinically significant adverse reactions were reported. Some clinical signs were observed during field studies n=297 which were similar for carprofen- and placebo-treated dogs. Incidences of the following were observed in both groups: vomiting 4%, diarrhea 4%, changes in appetite 3%, lethargy 1.4%, behavioral changes 1%, and constipation 0.3%. The product vehicle served as control.

    There were no serious adverse events reported during clinical field studies of osteoarthritis with once daily administration of 2 mg/lb. The following categories of abnormal health observations were reported. The product vehicle served as control.

    Percentage of Dogs with Abnormal Health Observations Reported in Osteoarthritis Field Study 2 mg/lb once daily


    Rimadyl n=129

    Placebo n=132







    Diarrhea/Soft stool



    Behavior change









    SAP increase



    ALT increase



    AST increase



    BUN increase









    Clinical pathology parameters listed represent reports of increases from pre-treatment values medical judgement is necessary to determine clinical relevance.

    During investigational studies of surgical pain for the caplet formulation, no clinically significant adverse reactions were reported. The product vehicle served as control.

    Percentage of Dogs with Abnormal Health Observations Reported in Surgical Pain Field Studies with Caplets 2 mg/lb once daily


    Rimadyl n=148

    Placebo n=149




    Diarrhea/soft stool



    Ocular disease






    Dermatitis/skin lesion









    Oral/periodontal disease






    Urinary tract disease



    Wound drainage



    * A single dog may have experienced more than one occurrence of an event.

    Post-Approval Experience:

    Although not all adverse reactions are reported, the following adverse reactions are based on voluntary post-approval adverse drug experience reporting. The categories of adverse reactions are listed in decreasing order of frequency by body system.

    Gastrointestinal: Vomiting, diarrhea, constipation, inappetence, melena, hematemesis, gastrointestinal ulceration, gastrointestinal bleeding, pancreatitis.

    Hepatic: Inappetence, vomiting, jaundice, acute hepatic toxicity, hepatic enzyme elevation, abnormal liver function tests, hyperbilirubinemia, bilirubinuria, hypoalbuminemia. Approximately one-fourth of hepatic reports were in Labrador Retrievers.

    Neurologic: Ataxia, paresis, paralysis, seizures, vestibular signs, disorientation.

    Urinary: Hematuria, polyuria, polydipsia, urinary incontinence, urinary tract infection, azotemia, acute renal failure, tubular abnormalities including acute tubular necrosis, renal tubular acidosis, glucosuria.

    Behavioral: Sedation, lethargy, hyperactivity, restlessness, aggressiveness.

    Hematologic: Immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, blood loss anemia, epistaxis.

    Dermatologic: Pruritus, increased shedding, alopecia, pyotraumatic moist dermatitis hot spots, necrotizing panniculitis/vasculitis, ventral ecchymosis.

    Immunologic or hypersensitivity: Facial swelling, hives, erythema.

    In rare situations, death has been associated with some of the adverse reactions listed above.

    To report a suspected adverse reaction call 1-800-366-5288.


    STORAGE: Store at controlled room temperature 15°-30°C 59°-86°F.